NCEL
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock is fundamentally valueless based on traditional accounting metrics.
- Negative Price/Book ratio
- No earnings for P/E calculation
- No Graham Number available
Future viability is highly questionable without immediate capital infusion.
- Biotech sector potential
- No revenue growth data
- Extreme cash burn implied by ROA
Historical performance shows a total collapse of shareholder value.
- 5Y Change: -99.8%
- 1Y Change: -82.6%
- Crash from 52-week high of $30.80
Financial health is in a state of failure; Altman Z-Score cannot be calculated due to negative equity.
- Piotroski F-Score 1/9
- Current Ratio 0.02
- Negative ROA
Dividends are non-existent and unrealistic given the balance sheet.
- 0/100 Dividend Strength
- No dividend history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NCEL and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NCEL
NewcelX Ltd.
Primary
|
-99.8% | -99.6% | -82.6% | -85.8% | -5.6% | +21.1% |
|
BNGO
Bionano Genomics, Inc.
Peer
|
-100.0% | -99.8% | -64.6% | -35.8% | +0.9% | +3.6% |
|
GDTC
CytoMed Therapeutics Limited
Peer
|
-75.0% | -75.0% | -63.5% | -55.6% | -5.7% | +1.2% |
|
NXL
Nexalin Technology, Inc.
Peer
|
-77.4% | -35.6% | -70.6% | -64.9% | +25.1% | +45.4% |
|
CUPR
Cuprina Holdings (Cayman) Limited
Peer
|
-85.5% | -85.5% | -85.5% | -45.3% | +62.6% | +105.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q2 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NCEL
NewcelX Ltd.
|
BEARISH | $11.49M | - | -% | -% | $2.52 | |
|
BNGO
Bionano Genomics, Inc.
|
BEARISH | $11.7M | - | -78.2% | -134.4% | $1.15 | Compare |
|
GDTC
CytoMed Therapeutics Limited
|
BEARISH | $11.83M | - | -50.3% | -% | $1.0 | Compare |
|
NXL
Nexalin Technology, Inc.
|
BEARISH | $10.48M | - | -221.5% | -% | $0.51 | Compare |
|
CUPR
Cuprina Holdings (Cayman) Limited
|
BEARISH | $12.9M | - | -139.1% | -% | $0.6 | Compare |
Past News Coverage
Recent headlines mentioning NCEL from our newsroom.